| Source: |
| Type: measurement |
| Bioavailability (usually in %) absorbed by the body. |
| 2866- | HNK, | Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship |
| - | Review, | Var, | NA |
| 2865- | HNK, | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
| - | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2886- | HNK, | Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vivo, | NA, | NA |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2082- | HNK, | Revealing the role of honokiol in human glioma cells by RNA-seq analysis |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 2079- | HNK, | Honokiol Microemulsion Causes Stage-Dependent Toxicity Via Dual Roles in Oxidation-Reduction and Apoptosis through FoxO Signaling Pathway |
| - | in-vitro, | Nor, | PC12 |
| 7618- | HPT, | ESHO 2-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of advanced neck nodes: A randomized multicenter study by the European Society for Hyperthermic Oncology |
| - | Trial, | HNSCC, | NA |
| 7542- | HT, | Hydroxytyrosol Induces Apoptosis and Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B | - | in-vitro, | Nor, | RWPE-1 |
| 7524- | HT, | The Pharmaceutical Formulation Plays a Pivotal Role in Hydroxytyrosol Pharmacokinetics |
| - | Trial, | Nor, | NA |
| 7525- | HT, | Pharmacokinetics and bioavailability of hydroxytyrosol are dependent on the food matrix in humans |
| - | Human, | Nor, | NA |
| 7526- | HT, | Hydroxytyrosol in functional hydroxytyrosol-enriched biscuits is highly bioavailable and decreases oxidised low density lipoprotein levels in humans |
| - | Trial, | Nor, | NA |
| 4639- | HT, | Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 4645- | HT, | Hydroxytyrosol: Bioavailability, toxicity, and clinical applications |
| - | Review, | Nor, | NA |
| 7480- | Hup, | Pharmacokinetics of huperzine A following oral administration to human volunteers |
| - | Trial, | AD, | NA |
| 7560- | HYP, | Hyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
| 7580- | I3C, | Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane |
| - | Trial, | Var, | NA |
| 7804- | IBC, | Isobavachalcone: A comprehensive review of its plant sources, pharmacokinetics, toxicity, pharmacological activities and related molecular mechanisms |
| - | Review, | Nor, | NA |
| 7636- | Ins, | Myo-Inositol: Pharmacokinetics, Biological Functions, and Therapeutic Potential in Liver Protection: Insights from Preclinical Models |
| - | Review, | Nor, | NA |
| 7634- | Ins, | Risk of reduced intestinal absorption of myo-inositol caused by D-chiro-inositol or by glucose transporter inhibitors |
| - | Trial, | Nor, | NA |
| 7633- | Ins, | Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use |
| - | Trial, | Nor, | NA |
| 7638- | Ins, | d-Chiro-Inositol in Clinical Practice: A Perspective from the Experts Group on Inositol in Basic and Clinical Research (EGOI) |
| - | Review, | Nor, | NA |
| 7641- | Ins, | Overview of Inositol and Inositol Phosphates on Chemoprevention of Colitis-Induced Carcinogenesis |
| - | Review, | CRC, | NA |
| 7685- | iod, | Could iodine be the missing micronutrient in breast cancer development? |
| - | Review, | BC, | NA |
| 7714- | IP6, | ACNs, | Enhanced absorption of anthocyanins after oral administration of phytic acid in rats and humans |
| - | in-vivo, | Nor, | NA |
| 7722- | IP6, | Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic |
| - | Review, | Var, | NA |
| 7729- | IP6, | Influence of concomitant food intake on the excretion of orally administered myo-inositol hexaphosphate in humans |
| - | Human, | Nor, | NA |
| 7743- | ISL, | Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration |
| - | in-vivo, | Nor, | NA |
| 7760- | ISL, | Pharmacological Potentials and Delivery Strategies of Isoliquiritigenin: Challenges and Advances in Enhancing Bioavailability |
| - | Review, | Nor, | NA |
| 7761- | ISL, | Targeting digestive system cancers with isoliquiritigenin: a comprehensive review of antitumor mechanisms |
| - | Review, | Var, | NA |
| 7763- | ISL, | Harnessing Liquiritigenin: A Flavonoid-Based Approach for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 7765- | ISL, | Isoliquiritigenin as a modulator of the Nrf2 signaling pathway: potential therapeutic implications |
| - | Review, | Var, | NA |
| 7781- | ISL, | Perspectives on the Role of Isoliquiritigenin in Cancer |
| - | Review, | Var, | NA |
| 7785- | ISL, | Enhancement of Oral Bioavailability and Anti-hyperuricemic Activity of Isoliquiritigenin via Self-Microemulsifying Drug Delivery System |
| - | in-vivo, | Nor, | NA |
| 9251- | ISO, IH, | Advances in Isorhamnetin Treatment of Malignant Tumors: Mechanisms and Applications |
| - | Review, | Var, | NA |
| 9250- | ISO, IH, | Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions |
| - | Study, | Nor, | NA |
| 7735- | isoFl, | Soy Isoflavones in Integrative Oncology: Increased Efficacy and Decreased Toxicity of Cancer Therapy |
| - | Review, | Var, | NA |
| 7732- | isoFl, | Biological activities and therapeutic potential of soy isoflavones: a focus on anticancer activity |
| - | Review, | Var, | NA |
| 7860- | isoO, | Metabolism and plasma pharmacokinetics of isoorientin, a natural active ingredient, in Sprague-Dawley male rats after oral and intravenous administration |
| - | in-vivo, | Nor, | NA |
| 7877- | isoO, | Isoorientin: A dietary flavone with the potential to ameliorate diverse metabolic complications |
| - | Review, | Nor, | NA |
| - | in-vivo, | Nor, | NA |
| 7795- | ISQ, | The Flavonol Isoquercitrin Promotes Mitochondrial-Dependent Apoptosis in SK-Mel-2 Melanoma Cell via the PI3K/AKT/mTOR Pathway |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vitro, | Nor, | HaCaT |
| 7791- | ISQ, | Isoquercitrin: pharmacology, toxicology, and metabolism |
| - | Review, | Nor, | NA |
| 7846- | ISQ, | Ninety-day toxicity and single-dose toxicokinetics study of alpha-glycosyl isoquercitrin in Sprague-Dawley rats |
| - | in-vivo, | Nor, | NA |
| 7841- | ISQ, | Enzymatically modified isoquercitrin improves endothelial function in volunteers at risk of cardiovascular disease |
| - | Human, | CardioV, | NA |
| 7848- | ISQ, | Review of anticancer mechanisms of isoquercitin |
| - | Review, | Var, | NA |
| 7559- | ISQ, | Difference in absorption of the two structurally similar flavonoid glycosides, hyperoside and isoquercitrin, in rats |
| - | in-vivo, | Nor, | NA |
| 9180- | ITCs, | SFN, | Epigenetics/epigenomics and prevention of early stages of cancer by isothiocyanates Review |
| - | Review, | Var, | NA |
| 9177- | ITCs, | SFN, | Dietary Isothiocyanates: Novel Insights into the Potential for Cancer Prevention and Therapy |
| - | Review, | Var, | NA |
| 9183- | ITCs, | PEITC, | Isothiocyanates: translating the power of plants to people |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:792 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid